AUTHOR INDEX

Abe, K.
See Nagata, K.
Abe, K., Saito, H. and Matsuki, N.
Vascular α-receptors and cytosolic Ca^{2+} 337
Abe, Y.
See Kimura, S.
Aburada, M.
See Ohkura, Y.
Akahane, K., Furukawa, Y., Karasawa, Y., Ren, L.-M. and Chiba, S.
Denopamine on dog heart 69
Araki, Y.
See Gomita, Y.
Ariyoshi, S.
See Ichida, S.
Asano, M.
Myosin phosphorylation 457
W-7 and myosin phosphorylation 471
Azuma, H.
See Makino, E.
Azuma, H., Funayama, N., Kubota, T. and Ishikawa, Masayuki
Endothelial regrowth after denudation 541

Caymaz, O.
See Ceyhan, B.
Ceyhan, B., Karaaslan, Y., Caymaz, O., Oto, A., Oram, E., Oram, A. and Ugurlu, S.
Effects of sublingual captopril and nifedipine 189
Chiba, S.
See Akahane, K.

Egashira, T.
See Nagai, T.
Endoh, M.
See Satoh, H.

Fujii, S.
See Oda, M.
Fujii, T.
See Nishiyama, I.
Fujii, W., Kuribara, H. and Tadokoro, S.
Effects of methamphetamine and scopolamine 533
Fujisue, T.
See Ichida, S.
Fujitani, B. and Wakitani, K.
Antithrombotic effect of OP-41483 123
Fujiwara, M.
See Ishida, Y.
Fukui, K.
See Kimura, S.
Fukuoka, M.
See Morikawa, K.

Funayama, N.
See Azuma, H.
Furukawa, Y.
See Akahane, K.
Furuno, K.
See Gomita, Y.

Gomi, Y.
See Morikawa, K.
See Suzuki, N.
Gomita, Y., Ichimaru, Y., Moriyama, M., Furuno, K., Suemaru, K., Osman, F.E. and Araki, Y.
Behavioral effects of HR-592 609
Goshima, Y.
See Ohno, K.
Goshima, Y., Nakamura, S. and Misu, Y.
A competitive antagonist for L-DOPA 174
Goto, Y.
See Hara, N.
See Yamasaki, K.
Goto, Y. and Ohno, H.
Antiulcer effect of elcatonin 379

Hagiwara, M., Ohuchi, E., Hongo, K., Oki, M., Wada, K., Morikawa, T. and Kobashi, K.
Pharmacology of sulfated angiotensin II 493
Hamano, S.
See Takehana, Y.
Hara, C.
See Watanabe, Kouki
Hara, N., Hara, Y. and Goto, Y.
GABA effect on gastric acid secretion 345
Hara, Y.
See Hara, N.
Hasegawa, N.
See Kasugai, S.
Hashimoto, K.
See Motomura, S.
Hattori, K.
See Kobayashi, Y.
Hattori, T., Ito, M., Nagamatsu, T. and Suzuki, Yoshio
Effect of TJ-8014 on crescentic nephritis 131
Hayashi, K.
See Kageyama, M.
Hayashi, M.
See Qu, X.F.
Hayashi, S.
See Kitamura, Y.
Hibi, N.
See Okamoto, Y.
Hirose, A.
See Tanaka, H.
Hisaki, K.
See Morimoto, S.

AUTHOR INDEX

Abe, K.
See Nagata, K.
Abe, K., Saito, H. and Matsuki, N.
Vascular α-receptors and cytosolic Ca^{2+} 337
Abe, Y.
See Kimura, S.
Aburada, M.
See Ohkura, Y.
Akahane, K., Furukawa, Y., Karasawa, Y., Ren, L.-M. and Chiba, S.
Denopamine on dog heart 69
Araki, Y.
See Gomita, Y.
Ariyoshi, S.
See Ichida, S.
Asano, M.
Myosin phosphorylation 457
W-7 and myosin phosphorylation 471
Azuma, H.
See Makino, E.
Azuma, H., Funayama, N., Kubota, T. and Ishikawa, Masayuki
Endothelial regrowth after denudation 541

Caymaz, O.
See Ceyhan, B.
Ceyhan, B., Karaaslan, Y., Caymaz, O., Oto, A., Oram, E., Oram, A. and Ugurlu, S.
Effects of sublingual captopril and nifedipine 189
Chiba, S.
See Akahane, K.

Egashira, T.
See Nagai, T.
Endoh, M.
See Satoh, H.

Fujii, S.
See Oda, M.
Fujii, T.
See Nishiyama, I.
Fujii, W., Kuribara, H. and Tadokoro, S.
Effects of methamphetamine and scopolamine 533
Fujisue, T.
See Ichida, S.
Fujitani, B. and Wakitani, K.
Antithrombotic effect of OP-41483 123
Fujiwara, M.
See Ishida, Y.
Fukui, K.
See Kimura, S.
Fukuoka, M.
See Morikawa, K.

Funayama, N.
See Azuma, H.
Furukawa, Y.
See Akahane, K.
Furuno, K.
See Gomita, Y.

Gomi, Y.
See Morikawa, K.
See Suzuki, N.
Gomita, Y., Ichimaru, Y., Moriyama, M., Furuno, K., Suemaru, K., Osman, F.E. and Araki, Y.
Behavioral effects of HR-592 609
Goshima, Y.
See Ohno, K.
Goshima, Y., Nakamura, S. and Misu, Y.
A competitive antagonist for L-DOPA 174
Goto, Y.
See Hara, N.
See Yamasaki, K.
Goto, Y. and Ohno, H.
Antiulcer effect of elcatonin 379

Hagiwara, M., Ohuchi, E., Hongo, K., Oki, M., Wada, K., Morikawa, T. and Kobashi, K.
Pharmacology of sulfated angiotensin II 493
Hamano, S.
See Takehana, Y.
Hara, C.
See Watanabe, Kouki
Hara, N., Hara, Y. and Goto, Y.
GABA effect on gastric acid secretion 345
Hara, Y.
See Hara, N.
Hasegawa, N.
See Kasugai, S.
Hashimoto, K.
See Motomura, S.
Hattori, K.
See Kobayashi, Y.
Hattori, T., Ito, M., Nagamatsu, T. and Suzuki, Yoshio
Effect of TJ-8014 on crescentic nephritis 131
Hayashi, K.
See Kageyama, M.
Hayashi, M.
See Qu, X.F.
Hayashi, S.
See Kitamura, Y.
Hibi, N.
See Okamoto, Y.
Hirose, A.
See Tanaka, H.
Hisaki, K.
See Morimoto, S.

Hongo, K.
See Hagiwara, M.
Hongo, T., Nojima, S. and Setaka, M.
Purification of gastric (H^++K^+)-ATPase 295
Horie, S.
See Yano, S.
Horiguchi, Y.
See Tani, T.
Hosokawa, Tadashi
See Kageyama, M.
Hosokawa, Tomokazu
See Misawa, M.
See Tsuchiya, Y.
Hosoya, E.
See Ohkura, Y.

Ichida, S., Yoshioka, K., Ariyoshi, S. and Fujisue, T.
Enhancement of Ca uptake by L-methionine 154
Ichihara, T.
See Morimoto, S.
Ichimaru, Y.
See Gomita, Y.
Iida, K.
See Okamoto, Y.
Ikeda, S.
See Nambu, F.
See Takehana, Y.
Imai, S.
See Tanaka, M.
Imoto, Y.
See Kuwahara, Y.
Imura, Y., Terashita, Z., Shibouta, Y., Inada, Y. and Nishikawa, K.
TXA_2/PGH_2 receptor antagonist, AA-2414 35
Inada, Y.
See Imura, Y.
Ino, Y.
See Oda, M.
Inoue, T.
See Kontani, H.
Ishida, Y., Mizukami, M., Taniguchi, T., Satake, N., Fujiwara, M. and Shibata, S.
Disopyramide and anticholinergic action 363
Ishikawa, Masaaki, Takayanagi, Y. and Sasaki, K.
Cisplatin and buthionine sulfoximine 652
Ishikawa, Masayuki
See Azuma, H.
Ishitani, R.
See Serikyaku, S.
Ito, Keiichi
See Yano, S.
Ito, M.
See Hattori, T.
See Kojima, R.
Ito, M., Tanaka, T. and Suzuki, Yoshio
Anti-ulcer effect of Z-103 513
Ito, Y.
See Makino, E.
See Morikawa, K.
Itoh, Ken-ichi
See Okamoto, Y.
Iwaki, M.
See Oda, M.
Iwao, H.
See Kimura, S.
Iwata, N.
See Kobayashi, K.
Iyeda, N.
See Okamoto, Y.

Kageyama, M., Matsumura, Y., Hayashi, K., Hosokawa, Tadashi and Morimoto, S.
Renal action of nisoldipine 245
Kai, H., Yamamoto, S., Takahama, K. and Miyata, T.
Corticosterone and mucociliary transport 496
Kakinuma, Y.
See Okamoto, Y.
Kakiuchi, M.
See Morikawa, K.
Kambe, T.
See Okamoto, Y.
Kaneto, H.
See Takahashi, M.
Karaaslan, Y.
See Ceyhan, B.
Karaki, H.
See Ozaki, H.
Karasawa, A. and Kubo, K.
Benidipine and renal ischemia 553
Karasawa, Y.
See Akahane, K.
Kasugai, S., Hasegawa, N. and Ogura, H.
In vitro eugenol toxicity with MTT 95
Kasuya, Y.
See Tsuchiya, Y.
Kato, H.
See Makino, E.
See Morikawa, K.
Kawamura, M.
See Noguchi, A.
Kawasaki, A.
See Nambu, F.
Kikuchi, S.
See Takehana, Y.
Kimura, I.
See Kimura, M.
Kimura, M., Nakashima, N. and Kimura, I.
Salivary peptide P-C, insulin, glucagon 579
Kimura, S., Iwao, H., Fukui, K., Abe, Y. and Tanaka, S.
Thyroid hormone and angiotensinogen mRNA 281
Kimura, Y.

See Yano, S.
Kinami, J.
See Tsuchihashi, H.
Kitagawa, H.
See Ueno, K.
Kitamura, Y., Hayashi, S. and Nomura, Y.
WEB 1881 FU on brain M_1-mACh receptors 597
Kobashi, K.
See Hagiwara, M.
Kobayashi, K., Nakajima, E., Kubo, Y., Yasukawa, Y. and Iwata, N.
SAM ameliorates ischemic LCGU in the rat 141
Kobayashi, S.
See Okamoto, Y.
Kobayashi, Y. and Hattori, K.
Nitroarginine inhibits EDRF release 167
Koda, A.
See Makino, E.
Kodama, K.
See Tsuji, M.
Kojima, R., Ito, M. and Suzuki, Yoshio
Protective effect of PALP against TOB nephrotoxicity 11
Komatsu, H.
See Takehana, Y.
Kontani, H., Inoue, T. and Sakai, T.
Apomorphine on urinary bladder motility 59
Kubo, K.
See Karasawa, A.
Kubo, Y.
See Kobayashi, K.
Kubota, T.
See Azuma, H.
Kuga, T.
See Nishiyama, M.
Kumasaka, Y.
See Tanaka, H.
Kuramoto, S.
See Oda, M.
Kuribara, H.
See Fujii, W.
Kuribara, H. and Tadokoro, S.
YM-09151-2 and methamphetamine 489
Kuwahara, Y., Sunagawa, Y., Imoto, Y. and Okabe, S.
Oral hEGF on ulcer healing 164

Magaribuchi, T.
See Onoda, Y.
Makino, E., Ohashi, T., Takahashi, H., Kato, H., Ito, Y., Nagai, H., Koda, A. and Azuma, H.
Inhibition of PCA by HSR-6071 87
Masuda, Y.
See Taniguchi, K.
Matsubara, T.
See Okamoto, Y.
Matsuki, N.
See Abe, K.
See Nagata, K.
Matsumura, Y.
See Kageyama, M.
See Morimoto, S.
Minami, M.
See Takeuchi, K.
Misawa, M., Takahashi, Yoshinori, Hosokawa, Tomokazu and Yanaura, S.
Reflex tracheal dilatation 639
Misu, Y.
See Goshima, Y.
See Ohno, K.
Mitomi, A.
See Tanaka, M.
Miyajima, K.
See Okamoto, Y.
Miyata, T.
See Kai, H.
Mizoguchi, Y.
See Ohkura, Y.
Mizukami, M.
See Ishida, Y.
Mizuno, M.
See Yano, S.
Mori, T., Yanagisawa, T. and Taira, N.
Histamine on vascular tone and $Ca^{2+}i$ 263
Morikawa, K., Fukuoka, M., Kakiuchi, M., Kato, H., Ito, Y. and Gomi, Y.
Detrusor hyperreflexia induced by xylene 587
Morikawa, K., Kakiuchi, M., Fukuoka, M., Kato, H., Ito, Y. and Gomi, Y.
Cystometrography in conscious rats 405
Morikawa, T.
See Hagiwara, M.
Morimoto, S.
See Kageyama, M.
Morimoto, S., Matsumura, Y., Ohyama, Tadashi, Shinyama, H., Ichihara, T., Takahashi, Yoshiyuki and Hisaki, K.
Pressure diuresis by L-threo-DOPS 431
Morisawa, S.
See Ohkura, Y.
Moriyama, M.
See Gomita, Y.
Motoishi, M.
See Nambu, F.
Motomura, S. and Hashimoto, K.
Cardiovascular profile of mepirodipine 319

Nagai, H.
See Makino, E.
Nagai, T., Egashira, T. and Yamanaka, Y.
BF on ischemia-reperfusion lesion 383
Nagamatsu, T.
See Hattori, T.

Nagata, K., Abe, K., Wang, C.-H., Saito, H. and Matsuki, N.
Deficient relaxation in suncus trachea 115
Nagata, M. and Osumi, Y.
Nicotine and gastric motility 397
Nagatani, T., Yamamoto, T., Takao, K., Sugihara, T. and Ueki, S.
Effect of β-CCM on muricide 441
Nagatomo, T.
See Tsuchihashi, H.
Nagaya, K.
See Yoshino, Y.
Nakajima, E.
See Kobayashi, K.
Nakamura, K.
See Oda, M.
Nakamura, M.
See Tanaka, H.
Nakamura, S.
See Goshima, Y.
See Ohno, K.
Nakashima, N.
See Kimura, M.
Nakashima, Y.
See Tsuchihashi, H.
Nakazawa, M.
See Tanaka, M.
Nambu, F., Motoishi, M., Omawari, N., Okegawa, T., Kawasaki, A. and Ikeda, S.
Inhibition of experimental asthma by OKY-046 307
Niida, H.
See Takeuchi, K.
Nishida, T.
See Okamoto, Y.
Nishikawa, K.
See Imura, Y.
Nishiyama, I. and Fujii, T.
Functional development of thyroid C-cell 149
Nishiyama, M. and Kuga, T.
Effects of FTA on the brain stem 201
Noguchi, A., Takamura, M., Yamada, K., Tou, S. and Kawamura, M.
Effect of procaine on the steroidogenesis 81
Nojima, S.
See Hongo, T.
Nomura, Y.
See Kitamura, Y.

Oda, M., Ino, Y., Nakamura, K., Kuramoto, S., Shimamura, K., Iwaki, M. and Fujii, S.
Pharmacological studies on FUT-187 23
Ogawa, N.
See Watanabe, Kouki
Ogihara, M.
See Sunaga, K.
Oguchi, K.
See Okazaki, M.
See Tsuji, M.
Ogura, H.
See Kasugai, S.
Ohashi, T.
See Makino, E.
Oh-ishi, S.
See Qu, X.F.
Ohkura, Y., Mizoguchi, Y., Morisawa, S., Takeda, S., Aburada, M. and Hosoya, E.
Effect of TJN-101 on arachidonic cascade 331
Ohno, H.
See Goto, Y.
Ohno, K., Nakamura, S., Goshima, Y. and Misu, Y.
Carteolol and presynaptic β-adrenoceptors 643
Ohuchi, E.
See Hagiwara, M.
Ohyama, Tadashi
See Morimoto, S.
Ohyama, Tatsuya
See Ozaki, H.
Okabe, S.
See Kuwahara, Y.
See Takeuchi, K.
Okamoto, Y., Matsubara, T., Iyeda, N., Miyajima, K., Iida, K., Nishida, T., Kobayashi, S., Kakinuma, Y., Itoh, Ken-ichi, Hibi, N., Kambe, T. and Sakamoto, N.
Nipradilol on myocardial ischemia 371
Okamura, T.
See Toda, N.
Okazaki, M., Suzuki, M. and Oguchi, K.
Hyperlipidemia and thrombosis 353
Okegawa, T.
See Nambu, F.
See Takehana, Y.
Oki, M.
See Hagiwara, M.
Omawari, N.
See Nambu, F.
Onoda, Y., Takido, M., Magaribuchi, T. and Tamaki, H.
Gastric mucosal protection by TA-2711 631
Oram, A.
See Ceyhan, B.
Oram, E.
See Ceyhan, B.
Osman, F.E.
See Gomita, Y.
Osumi, Y.
See Nagata, M.
Oto, A.
See Ceyhan, B.
Ozaki, H., Ohyama, Tatsuya, Sato, K. and Karaki, H.
Cytosolic Ca^{2+} and vascular contraction 509

Qu, X.F., Hayashi, M., Yamaki, K. and Oh-ishi, S.
Dye leakage in mouse paw edema 500

Ren, L.-M.
See Akahane, K.

Saha, A.R.
See Ueno, K.
Saito, H.
See Abe, K.
See Nagata, K.
Saito, M.
See Serikyaku, S.
Sakai, T.
See Kontani, H.
Sakamoto, N.
See Okamoto, Y.
Sasaki, K.
See Ishikawa, Masaaki
Satake, N.
See Ishida, Y.
Sato, K.
See Ozaki, H.
Satoh, H. and Endoh, M.
Cyclic AMP in inotropic effect of E-1020 215
Satoh, T.
See Ueno, K.
Sekino, H.
See Yoshino, Y.
Senda, T.
See Takahashi, M.
Serikyaku, S., Saito, M. and Ishitani, R.
Thiol groups in tryptamine binding sites 51
Setaka, M.
See Hongo, T.
Shibata, H. and Yamamoto, I.
Prolonged elevation of IL 2 activity 523
Shibata, S.
See Ishida, Y.
Shibouta, Y.
See Imura, Y.
Shimamura, K.
See Oda, M.
Shimizu, H.
See Tanaka, H.
Shinyama, H.
See Morimoto, S.
Sudo, J.
See Suzuki, Yoshihiro
Suemaru, K.
See Gomita, Y.
Sugihara, T.
See Nagatani, T.
Sunaga, K. and Ogihara, M.
Diabetes and antihypertensive agents 449
Sunagawa, Y.
See Kuwahara, Y.
Suzuki, M.
See Okazaki, M.
Suzuki, N. and Gomi, Y.
Bicarbonate and Bay K 8644 413
Suzuki, T.
Studies on drug dependence in rodents 1
Suzuki, Yoshihiro and Sudo, J.
Cephaloridine nephrotoxicity 233
Suzuki, Yoshio
See Hattori, T.
See Ito, M.
See Kojima, R.
Suzuki-Nishimura, T.
See Yoshino, Y.

Tadokoro, S.
See Fujii, W.
See Kuribara, H.
Taira, N.
See Mori, T.
Takahama, K.
See Kai, H.
Takahashi, H.
See Makino, E.
Takahashi, M., Senda, T. and Kaneto, H.
Dual action mechanisms of KK-3 analgesia 573
Takahashi, Yoshinori
See Misawa, M.
Takahashi, Yoshiyuki
See Morimoto, S.
Takamura, M.
See Noguchi, A.
Takanaka, K.
See Taniguchi, K.
Takao, K.
See Nagatani, T.
Takayanagi, Y.
See Ishikawa, Masaaki
Takeda, S.
See Ohkura, Y.
Takehana, Y., Hamano, S., Kikuchi, S., Komatsu, H., Okegawa, T. and Ikeda, S.
OKY-046·HCl on airway hyperresponsiveness 621
Takeuchi, K., Niida, H., Minami, M. and Okabe, S.
Duodenal alkaline secretion 225
Takido, M.
See Onoda, Y.
Tamaki, H.
See Onoda, Y.
Tanaka, H., Shimizu, H., Tatsuno, T., Hirose, A., Kumasaka, Y. and Nakamura, M.
SM-3997 binding sites in the rat brain 504
Tanaka, M., Yoshida, Y., Mitomi, A., Nakazawa, M. and Imai, S.
Felodipine and cerebral circulation 273
Tanaka, S.

See Kimura, S.
Tanaka, T.
See Ito, M.
Tani, T. and Horiguchi, Y.
Formaldehyde on cardiac function 563
Taniguchi, K., Masuda, Y. and Takanaka, K.
Antiallergic drugs and leukotriene 101
Taniguchi, T.
See Ishida, Y.
Tatsuno, T.
See Tanaka, H.
Terashita, Z.
See Imura, Y.
Toda, N. and Okamura, T.
L-NMMA on nerve function 170
Tou, S.
See Noguchi, A.
Tsuchihashi, H., Nakashima, Y., Kinami, J. and Nagatomo, T.
β-Adrenoceptors and $5HT_{1B}$-receptors 195
Tsuchiya, Y., Hosokawa, Tomokazu and Kasuya, Y.
Tracheal neurotransmission and histamine 647
Tsuji, M., Kodama, K. and Oguchi, K.
Effect of SAMe on hepatotoxicity 209
Membrane effects of SAMe 45

Uchida, M.K.
See Yoshino, Y.
Ueki, S.
See Nagatani, T.
Ueno, K., Saha, A.R., Kitagawa, H. and Satoh, T.
HAA elevated cAMP level in splenocytes 483
Ugurlu, S.
See Ceyhan, B.

Wada, K.
See Hagiwara, M.
Wakitani, K.
See Fujitani, B.
Wang, C.-H.
See Nagata, K.
Watanabe, Kazuo
See Yano, S.
See Yogo, K.
Watanabe, Kouki, Hara, C. and Ogawa, N.
Activity-stress ulcer and biorhythm 421
Watanabe, Y.
Adrenoceptor-mediated responses 179

Yagasaki, O.
See Yokoyama, K.
Yamada, K.
See Noguchi, A.
Yamada, N.
See Yano, S.
Yamaki, K.
See Qu, X.F.
Yamamoto, I.
See Shibata, H.
Yamamoto, S.
See Kai, H.
Yamamoto, T.
See Nagatani, T.
Yamanaka, Y.
See Nagai, T.
Yamasaki, K. and Goto, Y.
GABA-related compounds on gastric acid secretion 255
Yanagisawa, T.
See Mori, T.
Yanaura, S.
See Misawa, M.
Yano, S.
See Yogo, K.
Yano, S., Kimura, Y., Horie, S., Ito, Keiichi, Yamada, N., Mizuno, M. and Watanabe, Kazuo
Antisecretory effect of KW-5805 287
Yasukawa, Y.
See Kobayashi, K.
Yogo, K., Yano, S. and Watanabe, Kazuo
Endothelin and gastric vasoconstriction 160
Yokoyama, K. and Yagasaki, O.
Ca^{2+} blockers and acetylcholine release 109
Yoshida, Y.
See Tanaka, M.
Yoshino, Y., Nagaya, K., Sekino, H., Uchida, M.K. and Suzuki-Nishimura, T.
Mechanisms of mast cell activation by polycations 387
Yoshioka, K.
See Ichida, S.

SUBJECT INDEX

AA-2414 ((±)-7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid) 35
Acetic acid ulcer 164
Acetylcholine release 109
Acid secretion 345
Active metabolite 287
Activity-stress 421
S-Adenosyl-L-methionine 45, 141, 209
ADP-ribosylation 179
β-Adrenergic response 115
Adrenoceptor 179
β-Adrenoceptor 195
Adrenocortical cell 81
Airway hyper responsiveness 621
Alkaline secretion 225
Ambulatory activity (mouse) 533
L-Amino acid decarboxylase 431
Aminoglycoside nephrotoxicity 11
5-Aminovaleric acid 255
Angiotensin II 245
Angiotensinogen mRNA 281
Antiallergic action 87
Antiallergic drug 101
Antidiuresis 245
Antihypertensive agents 449
Antimuscarinic action 363
Antiplatelet agent 123
Antisecretory action 287
Antithrombotic agent 123
Antiulcer activity 379
Apomorphine 59
Arachidonic acid 101
Arachidonic acid cascade 331
Arginine-induced glucagon release 579
Arylsulfotransferase 493
Atrioventricular nodal conduction 319
Autoimmune 523

Baclofen 345
Bay K 8644 413
Behavioral effects 609
Benidipine 553
Benzamide derivative 489
Benzodiazepine receptors 441
Bethanechol 287
Bicarbonate 413
Bicuculline 345
Bifemelane hydrochloride 383
Bipyridine derivatives 215
Bladder function 405
β-Blockade 639
BM-13505 (4-[2-(4-chlorobenzene sulphonamide) ethyl] phenylacetic acid) 35
Brain (rat) 195, 597
Bronchoconstriction 307
Brush border membranes 11
Buthionine sulfoximine 652

C-cell 149
Ca^{2+} blockers 109
Ca^{2+}-calmodulin 457, 471
Ca^{2+} uptake 154, 621
Calcitonin 379
Calcitonin secretion 149
Calcium antagonists 273, 553
Calcium channel 413
Calcium overload 553
Calmodulin antagonists 471
Capsaicin 573
Captopril 189
β-Carboline 441
Carteolol 643
Catecholamine release 69
CCl_4 209
β-CCM (methyl-β-carboline-3-carboxylate) 441
Central nicotinic receptor 397
Cephaloridine 233
Cerebral artery 170
Cerebral circulation 273
β-(p-Chlorophenyl)-GABA (PCPGABA) 255
Cholinergic transmission 647
Chronobiology 421
Cisplatin 652
CNS depressants 1
Coagulative activity 353
Complement 23
Compound 48/80 387
Concanavalin A 483
Conscious rat 405, 587
Contractile force 319
Convulsion 201
Coronary artery (porcine) 263
Coronary vascular selectivity 319
Corticosterone 496
Crescent formation 131
Cross interaction 533
Cyclic AMP 215, 483
Cystometrography 405, 587
Cytosolic Ca^{2+} level 509

Defensive factor 631
Denopamine 69
Dental pulp 95
2-Deoxy-D-glucose 287
Detrusor hyperreflexia 587
Dibutyryl cyclic AMP 81
^{3}[H]Dihydroalprenolol binding 115
L-threo-3,4-Dihydroxyphenylserine (L-threo-

DOPS) 431
Disopyramide 363
L-DOPA 174
L-DOPA methyl ester 174
Duodenum 225
Dye leakage 500

E-1020 (1,2-dihydro-6-methyl-2-oxo-5-(imidazo-(1,2-a)pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate) 215
Endogenous prostaglandins 631
Endothelial cells 541
Endothelin 160
Endothelium 167
Erythrocytes 45
Eugenol toxicity 95

Felodipine 273
Fetus (rat) 149
Fibrinolysis 353
Formaldehyde 563
Forssman shock 23
Fumitremorgin A 201
Fura-2 263, 337
FUT-175 (nafamostat mesilate, 6-amidino-2-naphthyl p-guanidinobenzoate dimethanesulfonate) 23
FUT-187 (6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethane sulfonate) 23

GABA 255
GABA-mimetics 345
Gastric acid secretion 255
Gastric lesions 421
Gastric motility 397
Gastric mucosa (hog) 295
Gastric mucosal protection 631
Gastric ulcer 513
Glucocorticoid 523
Glucose 579
Glucose-induced insulin release 579
Gomisin A 331
GTP-binding protein 179

$(H^+ + K^+)$-ATPase 295
Haloperidol 59
Heart (dog) 69
Heart (guinea pig and rabbit) 563
Heart preparations (isolated) 563
Hepatocytes 45
Hepatotoxicity 209
Heptaminol AMP amidate (N-(1,5-dimethyl-5-hydroxy) hexyladenosine-5'-phosphoramidate) 483
High energy phosphate 371
Histamine 263, 647
Histamine release 87
Histopathology 131
HR-592 (5-chloro-3-(1,2,3,6-tetrahydro-1-propyl-4-pyridyl)indole) 609
HSR-6071 (6-(1-pyrrolidinyl)-N-(1H-tetrazol-5-yl)-2-pyrazinecarboxamide) 87
5-HT_{1A} 504
5-HT_{1B}-serotonergic receptor 195
Human epidermal growth factor (hEGF) 164
Hyperlipidemia 353
Hypertensive emergency 189
Hypogastric nerve 405
Hypothalamic slices (rat) 643
Hypothalamus 174

Interleukin 2 523
Intestinal smooth muscles 363
Intimal thickening 541
Intracellular calcium (level) 81, 263
Intracellular free Ca^{2+} concentration ($[Ca^{2+}]_i$) 337
Intrathecal injection 573
^{125}I-Iodocyanopindolol 195
Ischemia 141
Ischemia-reperfusion 383
Islet activating protein 387
Isoguvacine 255
Isoproterenol 115

Japanese herbal medicine 131

Kidney 233
KK-3 (tyrosyl-N-methyl-γ-aminobutylyl-phenylalaninol) 573
KW-5805 (5-[2-(diethylamino)ethyl]amino-5,11-dihydro[1]benzoxepino[3,4-b]pyridine trihydrochloride) 287

Lectins 387
^{14}C-Leucine 209
Leukotriene B_4 331
Leukotrienes 101, 307
Lipid peroxidation 233, 553
Lithium clearance 245
Liver 281, 383
Local cerebral glucose utilization (LCGU) 141
Lung inflation 639

M_1-muscarinic receptor 363, 597
M_2-muscarinic receptor 363
Mast cell 387
Mepirodipine 319
Methamphetamine 489, 533
L-Methionine 45, 154, 209
Metyrapone 496
Microsome 233
Mitochondrial function 371
Mitogen 483
L-N^G-Monomethyl arginine 170

MTT (3-(4,5)-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide) assay 95
Mucociliary transport 496
Muricide 441
Myenteric plexus 109
Myocardial ischemia 371
Myosin light chain phosphorylation 457, 471

Na^+,K^+-ATPase 45
Nephritis 131
Neutrophils 101
Nicardipine 273
Nicotine 397
Nifedipine 189, 413
Nipradilol 371
Nisoldipine 245
Nitric oxide 170
Nitroarginine 167
Nootropic 597
Norepinephrine 431

8-OH-DPAT 504
OKY-046 ((E)-3-[p-(1H-imidazol-1-ylmethyl) phenyl]-2-propenoic acid) 307
OP-41483 (5-(E)-6,9-deoxa-6,9α-methylene-15-cyclopentyl-16,17,18,19,20-pentanor-PGI_2) 123
Opioid κ-receptors 573
Opioids 1
Oxygen radicals 233

Passive cutaneous anaphylaxis 87
Paw edema (mouse) 500
Peripheral α-adrenergic mechanism 397
Pertussis toxin 179
pH deflection 225
Phaclofen 345
Phosphorylation 179
Physical dependence 1
Phytohemagglutinin P 483
Plasma glucose 449
Platelet activating factor (PAF) 307, 500
Polycation 387
Positive inotropic effect 215
Postsynaptic α-adrenoceptor subtypes 337
Potential difference 225
Precultivation 523
Pressure diuresis 431
Presynaptic β-adrenoceptors 643
Procaine 81
Prostaglandin 225, 379
Prostaglandin I_2 analog 123
Prostanoids 587
Protective effect 11
Proteinuria 131
Psychic dependence 1
Pyridoxal-5-phosphate 11

^{3}H-Quinuclidinyl benzilate (QNB) binding assay 363

Receptor-activation 509
Receptor assay 621
β-Receptor subtype 69
Reflex tracheal dilatation 639
Regeneration 541
Regeneration of mucosa 513
Regional myocardial blood flow 371
Relapsed ulcer 513
Renal failure 553
Renal function 431
Renin mRNA 281
Repeated administration 533
Repeated Ficoll gradient centrifugation 295
Reperfusion 141
Restraint stress 523
Reticular formation 201

Salivary peptide P-C 579
Saralasin 245
SCH 23390 59
Schisandra fruits 331
Scopolamine 533
Separation of myosin 457
Serine protease 23
Sex differences 421
Sinoatrial node automaticity 319
SM-3997 (3aα,4β,7β,7aα-hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)-butyl)-4,7-methano-1H-isoindole-1,3(2H)-dione dihydrogen citrate) 504
Smooth muscle contraction 457, 471
Spinal analgesia 573
Steroidogenesis 81
Stomach 160
Streptozotocin-diabetic rats 449
Sublingual administration 189
Sulfated angiotensin-II 493
12-Sulfodehydroabietic acid monosodium salt 631
Sulpiride 59
Suncus murinus 115
Superoxide 101
Sympathectomy 405
Sympathetic nervous activity 563

Tail artery (rat) 337
Temperature-sensitive high-affinity binding sites 51
Thiol reagents 51
Thoracic aorta 167
Thromboxane A_2 (TXA_2) 307, 621
Thromboxane A_2 (TXA_2)/prostaglandin endoperoxide (PGH_2) receptor antagonist 35
Thromboxane synthetase inhibitor 621
Thyroid hormone 281
TJN-101 (Gomisin A) 331

Tobramycin 11
Toxicity 652
Trachea 115, 647
Triton WR-1339 (p-isooctylpolyoxy-ethylenphenol formaldehyde polymer) 353
Tryptamine 51
[^{3}H]Tryptamine binding 51

U-44069 (15(S)-hydroxy-9α,11α-(epoxymethano) prosta-5Z,13E-dienoic acid) 35
U-46619 (15(S)-hydroxy-11α,9α-(epoxymethano) prosta-5Z,13E-dienoic acid) 35
Ulcer healing 164
Ulcer prediction 421
Urinary bladder 59
Uterus 154

Vas deferens (rat) 413
Vascular contraction 263
Vascular smooth muscle 509
Vasoconstriction 160
Ventricular myocardium (canine) 215

WEB 1881 FU (4-aminomethyl-1-benzylpyrrolidin-2-one-hemifumarate) 597

Xylene 587

YM-09151-2 (cis-N-(1-benzyl-2-methyl-pyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide) 489

Z-103 (N-(3-aminopropionyl)-L-histidinato zinc) 513